Patent Peace: A Rare Break in the Wild West of Generic Pharmaceuticals The recent patent settlement between Aurinia Pharmaceuticals and Teva Pharmaceuticals has sent shockwaves through the pharmaceutical industry.
On August 19, the two companies reached a major milestone, settling their U. S. patent dispute over Aurinia's flagship oral lupus nephritis drug, LUPKYNIS.
At first glance, this agreement may seem routine in the cutthroat world of Big Pharma. However, it marks a rare instance of cooperation between two industry giants.